Literature DB >> 32048533

Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial.

Marjut Laukka1, Susanna Mannisto, Annette Beule1, Mauri Kouri1, Carl Blomqvist1,2.   

Abstract

Introduction: To minimize the radiation exposure of mostly young testicular cancer patients, it is essential to find out whether CT could be replaced by magnetic resonance imaging (MRI) in the staging and follow-up of the patients. In this trial, we examined whether abdominal MRI is as effective as computed tomography (CT) in the detection of retroperitoneal metastases of testicular cancer.Material and methods: This prospective study included 50 patients, 46 cases of retroperitoneal metastases and 4 controls without abdominal metastases (mean age 33, 5 years, range 20-65 years). Imaging of the retroperitoneum was performed using CT and 1.5 T MRI with diffusion weighted imaging (DWI). One experienced radiologist re-analyzed all of the examinations without knowledge of clinical information. All metastatic or suspicious lymph nodes were noted and measured two-dimensionally from axial images. Nodal detection and the size of detected nodes on CT and MRI were compared.
Results: There was no significant difference in the detection of retroperitoneal metastasis between CT and MRI. The sensitivity of MRI was 0.98. There was no statistically significant difference in the sizes of lymph nodes found in CT and MRI, and even very small lymph nodes could be detected in MRI as well as in CT.
Conclusion: MRI with DWI is as good as CT in detection of retroperitoneal lymph node metastases regardless of lymph node size, and it can be used as part of follow-up of testicular cancer patients instead of ionizing radiation producing imaging methods.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32048533     DOI: 10.1080/0284186X.2020.1725243

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review.

Authors:  Jonas Busch; Stefanie Schmidt; Peter Albers; Julia Heinzelbecker; Sabine Kliesch; Julia Lackner; David Pfister; Christian Ruf; Christian Winter; Friedemann Zengerling; Dirk Beyersdorff
Journal:  World J Urol       Date:  2022-01-17       Impact factor: 4.226

2.  Magnetic resonance versus computed tomography for the detection of retroperitoneal lymph node metastasis due to testicular cancer: A systematic literature review.

Authors:  Andrés Felipe Herrera Ortiz; Lorena Josefina Fernández Beaujon; Sandra Yulitza García Villamizar; Freddy Fernando Fonseca López
Journal:  Eur J Radiol Open       Date:  2021-08-17

Review 3.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

4.  Whole Body MRI in the Detection of Lymph Node Metastases in Patients with Testicular Germ Cell Cancer.

Authors:  Vassiliki Pasoglou; Sandy Van Nieuwenhove; Julien Van Damme; Nicolas Michoux; Aline Van Maanen; Laurence Annet; Jean-Pascal Machiels; Bertrand Tombal; Frederic E Lecouvet
Journal:  Life (Basel)       Date:  2022-01-29

Review 5.  Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging.

Authors:  Gamal Anton Wakileh; Christian Ruf; Axel Heidenreich; Klaus-Peter Dieckmann; Catharina Lisson; Vikas Prasad; Christian Bolenz; Friedemann Zengerling
Journal:  World J Urol       Date:  2021-11-15       Impact factor: 4.226

Review 6.  The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls.

Authors:  Thibaut Pierre; Fatine Selhane; Elise Zareski; Camilo Garcia; Karim Fizazi; Yohann Loriot; Anna Patrikidou; Natacha Naoun; Alice Bernard-Tessier; Hervé Baumert; Cédric Lebacle; Pierre Blanchard; Laurence Rocher; Corinne Balleyguier
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.